Efficacy and Safety of Transnasal CoolStat Cooling Device to Induce and Maintain Hypothermia

Fabrizio R. Assis, M. Emma G. Bigelow, Raghuram Chava, Sunjeet Sidhu, Aravindan Kolandaivelu, Henry R Halperin, Harikrishna Tandri

Research output: Contribution to journalArticle

Abstract

Targeted temperature management (TTM) is recommended as a standard of care for postcardiac arrest patients. Current TTM methods have significant limitations to be used in an ambulatory setting. We investigated the efficacy and safety of a novel noninvasive transnasal evaporative cooling device (CoolStat™). Eleven Yorkshire pigs underwent hypothermia therapy using the CoolStat device. CoolStat induces evaporative cooling by blowing dehumidified ambient air over the nasal turbinates in a unidirectional fashion. CoolStat's efficacy and safety were assessed by applying different cooling strategies (groups A, B and C). In group A (efficacy study; n = 5, TTM for 8 hours), time to achieve brain target temperature (2°C reduction from baseline), and the percentage of time in which the temperature ranged within ±0.5°C after reaching the target temperature were investigated. In the safety assessment (groups B and C), two worst-case therapy situations were reproduced: in group B (n = 3), continuous maximum air flow (65 L/min) was applied without temperature control and, in group C (n = 3), subjects underwent 24-hour TTM (prolonged therapy). Hemodynamic and respiratory parameters, nasal mucosa integrity (endoscopic assessment), and other therapy-related adverse effects were evaluated. Efficacy study: CoolStat cooling therapy successfully induced and sustained managed hypothermia in all subjects. Brain target temperature was achieved in 0.5 ± 0.6 hours and kept within a ±0.5°C range for the therapy duration (99.9% ± 0.1%). All animals completed the safety studies. Maximum air flow (group B) and 24-hour (group C) therapies were well tolerated and no significant damage was observed on nasal mucosa for neither of the groups. CoolStat was able to efficiently induce and maintain hypothermia using unidirectional high flow of dry air into the nostrils of porcine models. CoolStat therapy was well tolerated and no damage to nasal mucosa was observed under either maximum air flow or prolonged therapy.

Original languageEnglish (US)
Pages (from-to)108-117
Number of pages10
JournalTherapeutic Hypothermia and Temperature Management
Volume9
Issue number2
DOIs
StatePublished - Jun 1 2019

Fingerprint

Hypothermia
Safety
Equipment and Supplies
Temperature
Air
Nasal Mucosa
Therapeutics
Swine
Turbinates
Brain
Standard of Care
Group Psychotherapy
Nose
Hemodynamics
Control Groups

Keywords

  • cooling device
  • hypothermia
  • target temperature management
  • temperature control
  • transnasal

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Anesthesiology and Pain Medicine

Cite this

Efficacy and Safety of Transnasal CoolStat Cooling Device to Induce and Maintain Hypothermia. / Assis, Fabrizio R.; Bigelow, M. Emma G.; Chava, Raghuram; Sidhu, Sunjeet; Kolandaivelu, Aravindan; Halperin, Henry R; Tandri, Harikrishna.

In: Therapeutic Hypothermia and Temperature Management, Vol. 9, No. 2, 01.06.2019, p. 108-117.

Research output: Contribution to journalArticle

@article{1fa2c779226942a5b4b9a582f7075ef4,
title = "Efficacy and Safety of Transnasal CoolStat Cooling Device to Induce and Maintain Hypothermia",
abstract = "Targeted temperature management (TTM) is recommended as a standard of care for postcardiac arrest patients. Current TTM methods have significant limitations to be used in an ambulatory setting. We investigated the efficacy and safety of a novel noninvasive transnasal evaporative cooling device (CoolStat™). Eleven Yorkshire pigs underwent hypothermia therapy using the CoolStat device. CoolStat induces evaporative cooling by blowing dehumidified ambient air over the nasal turbinates in a unidirectional fashion. CoolStat's efficacy and safety were assessed by applying different cooling strategies (groups A, B and C). In group A (efficacy study; n = 5, TTM for 8 hours), time to achieve brain target temperature (2°C reduction from baseline), and the percentage of time in which the temperature ranged within ±0.5°C after reaching the target temperature were investigated. In the safety assessment (groups B and C), two worst-case therapy situations were reproduced: in group B (n = 3), continuous maximum air flow (65 L/min) was applied without temperature control and, in group C (n = 3), subjects underwent 24-hour TTM (prolonged therapy). Hemodynamic and respiratory parameters, nasal mucosa integrity (endoscopic assessment), and other therapy-related adverse effects were evaluated. Efficacy study: CoolStat cooling therapy successfully induced and sustained managed hypothermia in all subjects. Brain target temperature was achieved in 0.5 ± 0.6 hours and kept within a ±0.5°C range for the therapy duration (99.9{\%} ± 0.1{\%}). All animals completed the safety studies. Maximum air flow (group B) and 24-hour (group C) therapies were well tolerated and no significant damage was observed on nasal mucosa for neither of the groups. CoolStat was able to efficiently induce and maintain hypothermia using unidirectional high flow of dry air into the nostrils of porcine models. CoolStat therapy was well tolerated and no damage to nasal mucosa was observed under either maximum air flow or prolonged therapy.",
keywords = "cooling device, hypothermia, target temperature management, temperature control, transnasal",
author = "Assis, {Fabrizio R.} and Bigelow, {M. Emma G.} and Raghuram Chava and Sunjeet Sidhu and Aravindan Kolandaivelu and Halperin, {Henry R} and Harikrishna Tandri",
year = "2019",
month = "6",
day = "1",
doi = "10.1089/ther.2018.0014",
language = "English (US)",
volume = "9",
pages = "108--117",
journal = "Therapeutic hypothermia and temperature management",
issn = "2153-7658",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Efficacy and Safety of Transnasal CoolStat Cooling Device to Induce and Maintain Hypothermia

AU - Assis, Fabrizio R.

AU - Bigelow, M. Emma G.

AU - Chava, Raghuram

AU - Sidhu, Sunjeet

AU - Kolandaivelu, Aravindan

AU - Halperin, Henry R

AU - Tandri, Harikrishna

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Targeted temperature management (TTM) is recommended as a standard of care for postcardiac arrest patients. Current TTM methods have significant limitations to be used in an ambulatory setting. We investigated the efficacy and safety of a novel noninvasive transnasal evaporative cooling device (CoolStat™). Eleven Yorkshire pigs underwent hypothermia therapy using the CoolStat device. CoolStat induces evaporative cooling by blowing dehumidified ambient air over the nasal turbinates in a unidirectional fashion. CoolStat's efficacy and safety were assessed by applying different cooling strategies (groups A, B and C). In group A (efficacy study; n = 5, TTM for 8 hours), time to achieve brain target temperature (2°C reduction from baseline), and the percentage of time in which the temperature ranged within ±0.5°C after reaching the target temperature were investigated. In the safety assessment (groups B and C), two worst-case therapy situations were reproduced: in group B (n = 3), continuous maximum air flow (65 L/min) was applied without temperature control and, in group C (n = 3), subjects underwent 24-hour TTM (prolonged therapy). Hemodynamic and respiratory parameters, nasal mucosa integrity (endoscopic assessment), and other therapy-related adverse effects were evaluated. Efficacy study: CoolStat cooling therapy successfully induced and sustained managed hypothermia in all subjects. Brain target temperature was achieved in 0.5 ± 0.6 hours and kept within a ±0.5°C range for the therapy duration (99.9% ± 0.1%). All animals completed the safety studies. Maximum air flow (group B) and 24-hour (group C) therapies were well tolerated and no significant damage was observed on nasal mucosa for neither of the groups. CoolStat was able to efficiently induce and maintain hypothermia using unidirectional high flow of dry air into the nostrils of porcine models. CoolStat therapy was well tolerated and no damage to nasal mucosa was observed under either maximum air flow or prolonged therapy.

AB - Targeted temperature management (TTM) is recommended as a standard of care for postcardiac arrest patients. Current TTM methods have significant limitations to be used in an ambulatory setting. We investigated the efficacy and safety of a novel noninvasive transnasal evaporative cooling device (CoolStat™). Eleven Yorkshire pigs underwent hypothermia therapy using the CoolStat device. CoolStat induces evaporative cooling by blowing dehumidified ambient air over the nasal turbinates in a unidirectional fashion. CoolStat's efficacy and safety were assessed by applying different cooling strategies (groups A, B and C). In group A (efficacy study; n = 5, TTM for 8 hours), time to achieve brain target temperature (2°C reduction from baseline), and the percentage of time in which the temperature ranged within ±0.5°C after reaching the target temperature were investigated. In the safety assessment (groups B and C), two worst-case therapy situations were reproduced: in group B (n = 3), continuous maximum air flow (65 L/min) was applied without temperature control and, in group C (n = 3), subjects underwent 24-hour TTM (prolonged therapy). Hemodynamic and respiratory parameters, nasal mucosa integrity (endoscopic assessment), and other therapy-related adverse effects were evaluated. Efficacy study: CoolStat cooling therapy successfully induced and sustained managed hypothermia in all subjects. Brain target temperature was achieved in 0.5 ± 0.6 hours and kept within a ±0.5°C range for the therapy duration (99.9% ± 0.1%). All animals completed the safety studies. Maximum air flow (group B) and 24-hour (group C) therapies were well tolerated and no significant damage was observed on nasal mucosa for neither of the groups. CoolStat was able to efficiently induce and maintain hypothermia using unidirectional high flow of dry air into the nostrils of porcine models. CoolStat therapy was well tolerated and no damage to nasal mucosa was observed under either maximum air flow or prolonged therapy.

KW - cooling device

KW - hypothermia

KW - target temperature management

KW - temperature control

KW - transnasal

UR - http://www.scopus.com/inward/record.url?scp=85067040731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067040731&partnerID=8YFLogxK

U2 - 10.1089/ther.2018.0014

DO - 10.1089/ther.2018.0014

M3 - Article

C2 - 30234442

AN - SCOPUS:85067040731

VL - 9

SP - 108

EP - 117

JO - Therapeutic hypothermia and temperature management

JF - Therapeutic hypothermia and temperature management

SN - 2153-7658

IS - 2

ER -